Wanbury is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs) for global markets and sells branded drug formulations in India, specializing in treatments for diabetes, depression, and cough/cold.
The company possesses a narrow moat based on its significant global scale in specific molecules, holding a 10% market share in Metformin and 30% in Sertraline. However, the lack of durable pricing power is evident as net margins remain thin at 4.1% despite high ROCE, suggesting the business operates more as a high-efficiency commodity processor than a premium brand owner.
Historically, capital allocation was poor, characterized by high debt levels and a negative net worth that only recently turned positive. Current efforts are focused on deleveraging and modest capacity expansion in core APIs, but the high debt-to-equity ratio of 3.0 remains a significant constraint on value creation.
The company's precarious financial structure finally buckled when a minor cyclical downturn in API pricing met an inflexible debt burden. Despite high theoretical returns on capital, the thin 4.1% net margins provided no cushion for rising interest costs or regulatory hurdles. The 'going concern' warning from auditors proved prophetic as current liabilities overwhelmed liquid assets, forcing a fire sale of core assets or a dilutive restructuring that wiped out equity holders while the promoters remained insulated by their opaque physical shareholdings.
RichFakir rates Wanbury Ltd's business quality as poor — 32/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Wanbury Ltd is trading about 86% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Wanbury Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Wanbury Ltd's fair value is about ₹107 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →